Clinical Trial

A Trial of Ipatasertib in Combination With Atezolizumab

Study acronym: IceCAP
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated May 14, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single centre, proof-of-concept phase I trial of atezolizumab in combination with ipatasertib. There are two parts to this study, the dose escalation phase (Part A) and the dose expansion phase (Part B). Part A, will determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D). This will be followed by the Part B dose expansion phase to further characterise the safety and tolerability and to assess the pharmacodynamic activity of the combination.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2018-09-14; most recent amendment 2025-05-12.
Status change: Recruiting → Active, Not Recruiting 2025-05-12
Status change: Active, Not Recruiting → Recruiting 2020-11-16
Status change: Recruiting → Active, Not Recruiting 2020-04-08
Trial Details
NCT Number NCT03673787
Lead Sponsor Institute of Cancer Research, United Kingdom
Collaborators: Hoffmann-La Roche
Conditions Solid Tumor, Glioblastoma Multiforme, Prostate Cancer Metastatic
Enrollment 87 participants
Start Date 2018-08-13
Primary Completion 2026-03 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2025-05-14